GB0620259D0 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
GB0620259D0
GB0620259D0 GBGB0620259.2A GB0620259A GB0620259D0 GB 0620259 D0 GB0620259 D0 GB 0620259D0 GB 0620259 A GB0620259 A GB 0620259A GB 0620259 D0 GB0620259 D0 GB 0620259D0
Authority
GB
United Kingdom
Prior art keywords
salt
pharmaceutical compounds
combinations
provides
fomred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0620259.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Therapeutics Ltd
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Priority to GBGB0620259.2A priority Critical patent/GB0620259D0/en
Publication of GB0620259D0 publication Critical patent/GB0620259D0/en
Priority to TW096138174A priority patent/TWI429638B/zh
Priority to HUE12187611A priority patent/HUE037268T2/hu
Priority to CA2665931A priority patent/CA2665931C/en
Priority to RS20180350A priority patent/RS57079B1/sr
Priority to ES07824125T priority patent/ES2402903T3/es
Priority to HK09107894.3A priority patent/HK1128026B/en
Priority to NZ576110A priority patent/NZ576110A/en
Priority to HRP20130255TT priority patent/HRP20130255T1/hr
Priority to LTEP12187611.4T priority patent/LT2546233T/lt
Priority to MX2009003739A priority patent/MX2009003739A/es
Priority to RS20130118A priority patent/RS52716B/sr
Priority to PL12187611T priority patent/PL2546233T3/pl
Priority to PT121876114T priority patent/PT2546233T/pt
Priority to MEP-2013-34A priority patent/ME01874B/me
Priority to JP2009531915A priority patent/JP5726416B2/ja
Priority to AU2007306104A priority patent/AU2007306104B2/en
Priority to ES12187611.4T priority patent/ES2662359T3/es
Priority to EP12187611.4A priority patent/EP2546233B1/en
Priority to PCT/GB2007/003871 priority patent/WO2008044034A1/en
Priority to US12/445,130 priority patent/US8653084B2/en
Priority to BRPI0719879A priority patent/BRPI0719879A8/pt
Priority to DK12187611.4T priority patent/DK2546233T3/en
Priority to RU2009117589/04A priority patent/RU2490258C2/ru
Priority to PT78241254T priority patent/PT2081895E/pt
Priority to SI200732010T priority patent/SI2546233T1/en
Priority to PL07824125T priority patent/PL2081895T3/pl
Priority to DK07824125.4T priority patent/DK2081895T3/da
Priority to CN2007800455503A priority patent/CN101848892B/zh
Priority to EP07824125A priority patent/EP2081895B1/en
Priority to KR1020097009666A priority patent/KR101571568B1/ko
Priority to SI200731206T priority patent/SI2081895T1/sl
Priority to ZA2009/02270A priority patent/ZA200902270B/en
Priority to IL197934A priority patent/IL197934A/en
Priority to NO20091858A priority patent/NO342242B1/no
Priority to CY20131100278T priority patent/CY1113873T1/el
Priority to US14/149,450 priority patent/US9428439B2/en
Priority to HRP20180375TT priority patent/HRP20180375T1/hr
Priority to CY20181100318T priority patent/CY1120081T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/317—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/313—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of doubly bound oxygen containing functional groups, e.g. carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0620259.2A 2006-10-12 2006-10-12 Pharmaceutical compounds Ceased GB0620259D0 (en)

Priority Applications (39)

Application Number Priority Date Filing Date Title
GBGB0620259.2A GB0620259D0 (en) 2006-10-12 2006-10-12 Pharmaceutical compounds
TW096138174A TWI429638B (zh) 2006-10-12 2007-10-11 (2,4-二羥基-5-異丙基-苯基)-[5-(4-甲基-六氫吡-1-基甲基)-1,3-二氫-異吲哚-2-基]-甲酮之鹽及結晶型，中間體及製備方法，含彼之醫藥組成物，以及彼之用途
SI200731206T SI2081895T1 (sl) 2006-10-12 2007-10-12 Derivati hidrobenzamida kot zaviralci HSP90
EP12187611.4A EP2546233B1 (en) 2006-10-12 2007-10-12 Hydrobenzamide derivatives as inhibitors of hsp90
US12/445,130 US8653084B2 (en) 2006-10-12 2007-10-12 Hydrobenzamide derivatives as inhibitors of Hsp90
RS20180350A RS57079B1 (sr) 2006-10-12 2007-10-12 Derivati hidrobenzamida kao inhibitori proteina toplotnog šoka hsp90
ES07824125T ES2402903T3 (es) 2006-10-12 2007-10-12 Derivados de hidrobenzamida como inhibidores de la Hsp90
HK09107894.3A HK1128026B (en) 2006-10-12 2007-10-12 Hydrobenzamide derivatives as inhibitors of hsp90
NZ576110A NZ576110A (en) 2006-10-12 2007-10-12 Hydrobenzamide derivatives as inhibitors of hsp90
HRP20130255TT HRP20130255T1 (hr) 2006-10-12 2007-10-12 Derivati hidrobenzamida kao inhibitori hsp90
LTEP12187611.4T LT2546233T (lt) 2006-10-12 2007-10-12 Hidrobenzamido dariniai kaip hsp90 inhibitoriai
MX2009003739A MX2009003739A (es) 2006-10-12 2007-10-12 Derivados de hidrobenzamida como inhibidores de hsp90.
DK12187611.4T DK2546233T3 (en) 2006-10-12 2007-10-12 HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90
PL12187611T PL2546233T3 (pl) 2006-10-12 2007-10-12 Pochodne hydrobenzamidu jako inhibitory Hsp90
PT121876114T PT2546233T (pt) 2006-10-12 2007-10-12 Derivados de hidrobenzamida como inibidores de hsp90
MEP-2013-34A ME01874B (me) 2006-10-12 2007-10-12 Derivati hidrobebenzamida kao inhibitori proteina toplotnog šoka hsp90
JP2009531915A JP5726416B2 (ja) 2006-10-12 2007-10-12 Ｈｓｐ９０の阻害剤としてのヒドロベンズアミド誘導体
AU2007306104A AU2007306104B2 (en) 2006-10-12 2007-10-12 Hydrobenzamide derivatives as inhibitors of Hsp90
ES12187611.4T ES2662359T3 (es) 2006-10-12 2007-10-12 Derivados de hidrobenzamida como inhibidores de la Hsp90
HUE12187611A HUE037268T2 (hu) 2006-10-12 2007-10-12 Hidrobenzamid származékok, mint HSP90 inhibitorok
PCT/GB2007/003871 WO2008044034A1 (en) 2006-10-12 2007-10-12 Hydrobenzamide derivatives as inhibitors of hsp90
BRPI0719879A BRPI0719879A8 (pt) 2006-10-12 2007-10-12 sal de adição de ácido, processo para sua preparação e seu uso, bem como intermediário químico
CA2665931A CA2665931C (en) 2006-10-12 2007-10-12 Hydrobenzamide derivatives as inhibitors of hsp90
RS20130118A RS52716B (sr) 2006-10-12 2007-10-12 Derivati hidrobenzamida kao inhibitori proteina toplotnog šoka hsp90
RU2009117589/04A RU2490258C2 (ru) 2006-10-12 2007-10-12 ПРОИЗВОДНЫЕ ГИДРОБЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Hsp90
PT78241254T PT2081895E (pt) 2006-10-12 2007-10-12 Derivados de hidrobenzamida como inibidores de hsp90
SI200732010T SI2546233T1 (en) 2006-10-12 2007-10-12 HYDROBENZAMIDE DERIVATIVES AS FRAUDING HSP90
PL07824125T PL2081895T3 (pl) 2006-10-12 2007-10-12 POCHODNE HYDROBENZAMIDU JAKO INHIBITORY Hsp90
DK07824125.4T DK2081895T3 (da) 2006-10-12 2007-10-12 Hydrobenzamidderivater som hæmmere af hsp90
CN2007800455503A CN101848892B (zh) 2006-10-12 2007-10-12 作为hsp90抑制剂的氢化苯酰胺衍生物
EP07824125A EP2081895B1 (en) 2006-10-12 2007-10-12 Hydrobenzamide derivatives as inhibitors of hsp90
KR1020097009666A KR101571568B1 (ko) 2006-10-12 2007-10-12 Ｈｓｐ90의 억제제인 하이드로벤즈아미드 유도체
ZA2009/02270A ZA200902270B (en) 2006-10-12 2009-04-01 Hydrobenzamide derivatives as inhibitors of hsp90
IL197934A IL197934A (en) 2006-10-12 2009-04-05 History of hydrobenzamide as hsp90 inhibitors and their use in the treatment of disease
NO20091858A NO342242B1 (no) 2006-10-12 2009-05-12 Hydrobenzamid derivater som inhibitorer av HSP90, fremgangsmåter for fremstilling, farmasøytiske sammensetninger, kombinasjoner og anvendelser.
CY20131100278T CY1113873T1 (el) 2006-10-12 2013-04-03 Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
US14/149,450 US9428439B2 (en) 2006-10-12 2014-01-07 Hydrobenzamide derivatives as inhibitors of Hsp90
HRP20180375TT HRP20180375T1 (hr) 2006-10-12 2018-03-02 Derivati hidrobebenzamida kao inhibitori hsp90
CY20181100318T CY1120081T1 (el) 2006-10-12 2018-03-19 Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0620259.2A GB0620259D0 (en) 2006-10-12 2006-10-12 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
GB0620259D0 true GB0620259D0 (en) 2006-11-22

Family

ID=37491396

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0620259.2A Ceased GB0620259D0 (en) 2006-10-12 2006-10-12 Pharmaceutical compounds

Country Status (28)

Country Link
US (2) US8653084B2 (cg-RX-API-DMAC10.html)
EP (2) EP2546233B1 (cg-RX-API-DMAC10.html)
JP (1) JP5726416B2 (cg-RX-API-DMAC10.html)
KR (1) KR101571568B1 (cg-RX-API-DMAC10.html)
CN (1) CN101848892B (cg-RX-API-DMAC10.html)
AU (1) AU2007306104B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0719879A8 (cg-RX-API-DMAC10.html)
CA (1) CA2665931C (cg-RX-API-DMAC10.html)
CY (2) CY1113873T1 (cg-RX-API-DMAC10.html)
DK (2) DK2546233T3 (cg-RX-API-DMAC10.html)
ES (2) ES2662359T3 (cg-RX-API-DMAC10.html)
GB (1) GB0620259D0 (cg-RX-API-DMAC10.html)
HR (2) HRP20130255T1 (cg-RX-API-DMAC10.html)
HU (1) HUE037268T2 (cg-RX-API-DMAC10.html)
IL (1) IL197934A (cg-RX-API-DMAC10.html)
LT (1) LT2546233T (cg-RX-API-DMAC10.html)
ME (1) ME01874B (cg-RX-API-DMAC10.html)
MX (1) MX2009003739A (cg-RX-API-DMAC10.html)
NO (1) NO342242B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ576110A (cg-RX-API-DMAC10.html)
PL (2) PL2546233T3 (cg-RX-API-DMAC10.html)
PT (2) PT2081895E (cg-RX-API-DMAC10.html)
RS (2) RS52716B (cg-RX-API-DMAC10.html)
RU (1) RU2490258C2 (cg-RX-API-DMAC10.html)
SI (2) SI2081895T1 (cg-RX-API-DMAC10.html)
TW (1) TWI429638B (cg-RX-API-DMAC10.html)
WO (1) WO2008044034A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200902270B (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101193862B (zh) 2005-04-13 2013-08-21 阿斯特克斯治疗有限公司 羟基苯甲酰胺衍生物和其作为hsp90抑制剂的用途
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
JP5410285B2 (ja) * 2006-10-12 2014-02-05 アステックス、セラピューティックス、リミテッド 医薬化合物
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) * 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
CA2765678A1 (en) 2009-06-22 2010-12-29 Christopher Blackburn Substituted hydroxamic acids and uses thereof
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
GB201009853D0 (en) 2010-06-11 2010-07-21 Chroma Therapeutics Ltd HSP90 inhibitors
BR112014019704B1 (pt) * 2012-02-09 2022-05-31 University Of Kansas Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo
EA201492184A1 (ru) * 2012-05-25 2015-07-30 Берг Ллк Способы лечения метаболического синдрома путем модулирования белка теплового шока (hsp) 90-бета
US20180169117A1 (en) 2014-03-20 2018-06-21 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical formulation comprising a substituted phenyl - (1,3-dihydro-isoindol-2-yl) - methanone
WO2015188198A2 (en) 2014-06-06 2015-12-10 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
EP4093731A1 (en) * 2020-01-20 2022-11-30 Neophore Limited Isoindoline derivatives which bind to an atp binding site
GB202008201D0 (en) 2020-06-01 2020-07-15 Neophore Ltd Inhibitor compounds
CN114767683A (zh) * 2022-04-29 2022-07-22 暨南大学 Onalespib在制备预防和/或治疗腺病毒感染的药物中的应用
CN117700350A (zh) * 2023-03-31 2024-03-15 福建医科大学 一种靶向降解hsp90蛋白的化合物及其制备方法与应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5540563Y2 (cg-RX-API-DMAC10.html) 1972-04-26 1980-09-22
JPS4910506A (cg-RX-API-DMAC10.html) 1972-05-31 1974-01-30
US4582909A (en) * 1984-02-02 1986-04-15 Warner-Lambert Company Benzobicyclic lactam acids and derivatives as cognition activators
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4760064A (en) * 1984-12-18 1988-07-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
CA1340191C (en) 1988-06-13 1998-12-15 Katsuhiro Imaki Derivatives of p-substituted phenyl ester of pivalic acid
US4990511A (en) 1988-08-03 1991-02-05 Takeda Chemical Industries, Ltd. Amide compounds, their production and use
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
US5124350A (en) * 1990-06-28 1992-06-23 G. D. Searle & Co. Leukotriene b4 antagonists
CA2049481A1 (en) 1990-08-27 1992-02-28 Jill Ann Panetta Method of treating inflammatory bowel disease
FR2669029B1 (fr) 1990-11-14 1994-09-02 Adir Nouveaux derives de la n-benzoyl proline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5280046A (en) 1991-02-22 1994-01-18 The University Of Colorado Foundation, Inc. Method of treating type I diabetes
WO1992017467A1 (en) 1991-04-06 1992-10-15 Dr Lo. Zambeletti S.P.A. Substituted azacyclic compounds, process for their preparation and their use as analgesics
US5619092A (en) * 1993-02-01 1997-04-08 Motorola Enhanced electron emitter
US5633283A (en) 1995-01-23 1997-05-27 Eli Lilly And Company Method for treating multiple sclerosis
JPH0910506A (ja) 1995-06-30 1997-01-14 Toshiba Corp 脱気器
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
JP3855026B2 (ja) 1996-01-16 2006-12-06 富士レビオ株式会社 アミド誘導体の製造方法
ATE478672T1 (de) 1996-01-29 2010-09-15 Univ California Methode zur behandlung sexueller fehlfunktionen
GB9606187D0 (en) 1996-03-23 1996-05-29 Inst Of Food Research Production of vanillin
CA2249615A1 (en) 1996-04-03 1997-10-09 Robert Gomez Inhibitors of farnesyl-protein transferase
EP0918518A4 (en) 1996-04-19 2002-05-02 Univ California TREATMENT OF MIND AND MOOD DISEASES WITH GLUTAMATERGIC MODULATORS.
IL118657A0 (en) 1996-06-14 1996-10-16 Arad Dorit Inhibitors for picornavirus proteases
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
EP0973778A1 (en) 1997-03-07 2000-01-26 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
US6159979A (en) 1997-04-18 2000-12-12 Smithkline Beecham P.L.C. Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
US6166008A (en) 1997-10-27 2000-12-26 Cortex Pharmaceuticals, Inc. Treatment of schizophrenia with ampakines and neuroleptics
AU1804299A (en) 1997-12-08 1999-06-28 Glycomed Incorporated Sialyl lewis x and sialyl lewis a glycomimetics
EP1165492A1 (en) 1999-03-30 2002-01-02 Pharmacor Inc. Hydroxyphenyl derivatives with hiv integrase inhibitory properties
DE19955283A1 (de) 1999-11-17 2001-05-23 Aventis Res & Tech Gmbh & Co Verfahren zur enantioselektiven Gewinnung von Aminosäuren und Aminosäurederivaten unter Verwendung von Racemisierungskatalysatoren
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
AU2001243158A1 (en) 2000-02-18 2001-08-27 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
GB0008305D0 (en) * 2000-04-06 2000-05-24 Neutec Pharma Plc Treatment of fungal infections
JP2004507456A (ja) * 2000-05-11 2004-03-11 ブリストル−マイヤーズ　スクイブ　カンパニー 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
EP1283199A4 (en) 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANINE CONCENTRATING HORMONE ANTAGONISTS
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
DE10024939A1 (de) 2000-05-19 2001-11-29 Bayer Ag Neue Diphenylmethanderivate für Arzneimittel
FR2812876B1 (fr) * 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
AP2001002249A0 (en) 2000-08-25 2001-09-30 Warner Lambert Co Process for making N-ARYL-ANTHRANILIC acids and their derivatives.
WO2002049632A1 (en) 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
AU2002366362A1 (en) 2001-12-18 2003-06-30 Bayer Aktiengesellschaft 2-substituted pyrrolo(2.1-a)isoquinolines against cancer
KR20040068317A (ko) 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス（ケンブリッジ）リミテッド ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
EP1497268A4 (en) 2002-04-05 2006-01-18 Nitromed Inc NITROGEN OXIDE DISPENSER, COMPOSITIONS AND METHOD OF USE
CA2488342A1 (en) 2002-06-05 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Therapeutic drug for diabetes
EA009523B1 (ru) * 2002-06-05 2008-02-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Ингибиторы в отношении активации ар-1 и nfat
WO2003103658A1 (ja) * 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
AU2003242103A1 (en) * 2002-06-06 2003-12-22 Institute Of Medicinal Molecular Design, Inc Antiallergic agents
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
CN100354276C (zh) 2002-07-16 2007-12-12 阿姆拉医疗有限公司 生物活性化合物
JP2006505571A (ja) 2002-10-15 2006-02-16 リゲル ファーマシューテイカルズ、インコーポレイテッド 置換されたインドール及びｈｃｖ阻害剤としてのその使用
TWI228885B (en) 2003-01-23 2005-03-01 Mediatek Inc Method for controlling a mobile communication device to enter a power-saving mode and to recover timing after the mobile communication device leaves the power-saving mode
KR101166749B1 (ko) 2003-02-11 2012-07-27 베르날리스(캠브리지)리미티드 열쇼크 단백질 저해제로서의 이소옥사졸 화합물
JP2006514088A (ja) * 2003-02-20 2006-04-27 ユニバーシティー オブ コネティカット ヘルス センター 癌および感染症の治療における熱ショックタンパク質またはα−２−マクログロブリンを含む組成物の使用方法
JP2006518368A (ja) 2003-02-21 2006-08-10 ファイザー・インク プロテインキナーゼ阻害剤としてのｎ−ヘテロシクリル置換アミノチアゾール誘導体
US7432375B2 (en) 2003-03-06 2008-10-07 Eisai R & D Management Co., Ltd. JNK inhibitors
AU2004234067B2 (en) 2003-04-30 2008-02-28 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
AU2004251949B2 (en) 2003-06-27 2009-05-07 Kyowa Hakko Kirin Co., Ltd. Hsp90 family protein inhibitors
TWI322806B (en) 2003-06-30 2010-04-01 Mitsubishi Tanabe Pharma Corp Process of preparating 3-acylaminobenzofuran-2-carboxylic acid derivatives
US20070042997A1 (en) * 2003-07-16 2007-02-22 Akiko Itai Medicament for treatment of dermal pigmentation
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
RU2396250C2 (ru) 2003-07-24 2010-08-10 Лео Фарма А/С Новые производные аминобензофенона
WO2005012296A1 (en) 2003-07-28 2005-02-10 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
DE10335584B4 (de) * 2003-07-31 2006-06-29 Philipps-Universität Marburg Verfahren zur Herstellung zyklischer Moleküle
DE10335726A1 (de) * 2003-08-05 2005-03-03 Bayer Cropscience Gmbh Verwendung von Hydroxyaromaten als Safener
WO2005016889A1 (en) 2003-08-08 2005-02-24 Virginia Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties
EP1670804A2 (en) 2003-09-10 2006-06-21 GPC Biotech AG Heterobicyclic compounds as pharmaceutically active agents
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
CN1902171A (zh) 2003-11-10 2007-01-24 舍林股份公司 用作ccr－5拮抗剂的苄醚胺化合物
EP1704856A4 (en) 2003-12-26 2009-08-19 Kyowa Hakko Kirin Co Ltd PROTEIN INHIBITOR OF THE HSP90 FAMILY
US7351709B2 (en) * 2004-06-09 2008-04-01 Wyeth Estrogen receptor ligands
NZ553267A (en) 2004-07-27 2010-09-30 Sgx Pharmaceuticals Inc Pyrrolo-pyridine kinase modulators
BRPI0514504A (pt) 2004-08-20 2008-06-10 Univ Michigan pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas
DE102004049078A1 (de) 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
US7208630B2 (en) * 2004-10-27 2007-04-24 University Of Kansas Heat shock protein 90 inhibitors
US7781485B2 (en) * 2004-11-09 2010-08-24 Kyowa Hakko Kirin Co., Ltd. Hsp90 family protein inhibitors
ES2594874T3 (es) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
MX2007008008A (es) 2004-12-30 2007-11-12 Astex Therapeutics Ltd Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora.
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
WO2006082001A1 (en) * 2005-02-07 2006-08-10 F.Hoffmann-La Roche Ag Heterocyclic substituted phenyl methanones as inhibitors of the glycine transporter 1
WO2006088954A1 (en) * 2005-02-15 2006-08-24 Janssen Pharmaceutica, N.V. Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms
JPWO2006088193A1 (ja) 2005-02-21 2008-07-03 協和醗酵工業株式会社 抗腫瘍剤
CN101193862B (zh) * 2005-04-13 2013-08-21 阿斯特克斯治疗有限公司 羟基苯甲酰胺衍生物和其作为hsp90抑制剂的用途
JP2008540395A (ja) * 2005-05-03 2008-11-20 ファイザー・インク アミドレソルシノール化合物
SI1881823T1 (sl) 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
WO2007050124A1 (en) 2005-05-19 2007-05-03 Xenon Pharmaceuticals Inc. Fused piperidine derivatives and their uses as therapeutic agents
US7425633B2 (en) * 2005-08-26 2008-09-16 National Health Research Institutes Pyrrolidine compounds
PT1808634E (pt) * 2006-01-12 2008-12-11 Ondal Holding Gmbh Acessório de fixação para suportar um dispositivo
US7754725B2 (en) * 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US8883790B2 (en) * 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
JP5721949B2 (ja) * 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
US8916552B2 (en) * 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
JP5410285B2 (ja) 2006-10-12 2014-02-05 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2008053319A1 (en) 2006-10-30 2008-05-08 Pfizer Products Inc. Amide resorcinol compounds

Also Published As

Publication number Publication date
AU2007306104A1 (en) 2008-04-17
TWI429638B (zh) 2014-03-11
US9428439B2 (en) 2016-08-30
EP2546233B1 (en) 2018-02-21
ES2662359T3 (es) 2018-04-06
EP2081895B1 (en) 2013-01-23
HRP20180375T1 (hr) 2018-04-20
NO342242B1 (no) 2018-04-30
RU2009117589A (ru) 2010-11-20
MX2009003739A (es) 2009-09-04
EP2546233A1 (en) 2013-01-16
US20110046155A1 (en) 2011-02-24
JP2010505930A (ja) 2010-02-25
RU2490258C2 (ru) 2013-08-20
WO2008044034A1 (en) 2008-04-17
PT2546233T (pt) 2018-03-13
US20140221394A1 (en) 2014-08-07
CY1113873T1 (el) 2016-07-27
SI2546233T1 (en) 2018-04-30
EP2081895A1 (en) 2009-07-29
ZA200902270B (en) 2013-06-26
HK1128026A1 (en) 2009-10-16
IL197934A (en) 2014-01-30
CN101848892A (zh) 2010-09-29
CA2665931A1 (en) 2008-04-17
DK2081895T3 (da) 2013-04-22
PT2081895E (pt) 2013-04-10
PL2081895T3 (pl) 2013-07-31
RS52716B (sr) 2013-08-30
SI2081895T1 (sl) 2013-06-28
RS57079B1 (sr) 2018-06-29
NZ576110A (en) 2012-02-24
TW200833682A (en) 2008-08-16
JP5726416B2 (ja) 2015-06-03
CN101848892B (zh) 2013-08-21
ES2402903T3 (es) 2013-05-10
DK2546233T3 (en) 2018-03-19
CY1120081T1 (el) 2018-12-12
NO20091858L (no) 2009-07-08
LT2546233T (lt) 2018-03-26
CA2665931C (en) 2014-12-23
IL197934A0 (en) 2009-12-24
KR101571568B1 (ko) 2015-11-24
KR20090078825A (ko) 2009-07-20
AU2007306104B2 (en) 2014-11-06
BRPI0719879A8 (pt) 2018-03-13
HUE037268T2 (hu) 2018-08-28
US8653084B2 (en) 2014-02-18
ME01874B (me) 2014-12-20
BRPI0719879A2 (pt) 2014-06-10
HRP20130255T1 (hr) 2013-04-30
PL2546233T3 (pl) 2018-06-29

Similar Documents

Publication Publication Date Title
EP2107060A4 (en) PESTICIDES
WO2007018314A3 (en) Therapeutic agent for diabetes
CR9369A (es) Compuestos de peridil acido acetico
EP2385053A3 (en) Intermediates for the preparation of fused bicyclic mTOR inhibitors
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
ATE535527T1 (de) Verbindung mit affinität zu amyloid
WO2008059370A8 (en) Substituted bicyclocarboxyamide compounds
TW200833682A (en) Pharmaceutical compounds
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
WO2008047951A3 (en) An alzheimer' s disease progression inhibitor containing heterocyclic compound
WO2011064533A3 (en) Compositions containing a 3 - phenyluracil herbicide and a sulfamoylphenylurea safener
WO2007133481A3 (en) Method for increasing the bioavailability of benzhydryl piperazine containing compounds
ECSP088374A (es) Formulacion de aerosol para inhalacion
WO2009018551A3 (en) Therapeutic compounds
WO2007038425A3 (en) Anti-viral compouinds
IL186832A0 (en) Process for the preparation of a carboxamide derivatives
MX2010001304A (es) Compuestos terapeuticos.
PL1970372T3 (pl) Sole kwasu 9-oksoakrydyno-10-octowego z 1-alkiloamino-1-deoksypoliolami
EA200901085A1 (ru) Производные циклогексиламида арилкарбоновой кислоты
ATE456570T1 (de) Isothiazolopyridin-3-ylenamine zur bekämpfung tierischer schädlinge
WO2003091243A8 (en) Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
EP1749817A4 (en) COMPOSITION OF MEANS FOR COMBATING NEUROGENIC PAIN
NO20053997L (no) Oligosaccharidderivat
WO2007000392A3 (en) Chloro-substituted guanidines

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)